

8	4	2	1	8	4	2	1	8	4	2	1	8	4	2	1	8	4	2	1	8	4	2	1	8	4	2	1
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Marquer les cases d'un trait noir:

juste faux



Centre hospitalier universitaire vaudois
 Division de Pharmacologie Clinique, Service de Biomédecine
 Service des Maladies Infectieuses
 Réception des laboratoires: BH/18/100
 1011 Lausanne

Contact :
 Labo. : Tél.: 021 314 42 71 - Fax : 021 314 80 98 - PP 439
 Interprétation clinique : Tél.: 021 314 25 00
 www.chuv.ch/pcl

Ouverture du laboratoire :
 lundi - vendredi 08h00 - 17h00

Date and time of sampling (required)

Day:

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	
16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31

Month:

1	2	3	4	5	6	7	8	9	10	11	12
---	---	---	---	---	---	---	---	---	----	----	----

Hour:

0	1	2	3	4	5	6	7	8	9	10	11
12	13	14	15	16	17	18	19	20	21	22	23

 Min.:

15	30	45
----	----	----

Patient

Last name:

First name:

Gender:

Full birth date:

Address:

ZIP/City:

Your reference:

Invoice to:

patient applicant

Etiquette code barres pour le CHUV



COPY OF THE RESULTS TO:

Physician name:

Address:

ZIP/City:

REQUESTING PHYSICIAN:

Physician name:

Address:

Phone:

Etiquette déviation ou Etiquette de projet

CLINICAL JUSTIFICATION(S):

- | | |
|--|---|
| <input type="checkbox"/> Therapeutic Drug Monitoring | <input type="checkbox"/> Unclear compliance |
| <input type="checkbox"/> Infection not responding | <input type="checkbox"/> Pregnancy |
| <input type="checkbox"/> Suspected toxicity | <input type="checkbox"/> Study: |
| <input type="checkbox"/> Suspected drug interactions | <input type="checkbox"/> Other reason: |
| | <input type="checkbox"/> Urgent request (specify reason): |

INDICATION OF TREATMENT:

- | | | |
|--|---|---|
| <input type="checkbox"/> Prophylaxis | <input type="checkbox"/> 1 st line treatment | <input type="checkbox"/> Empirical therapy for persistent fever |
| <input type="checkbox"/> Pre-emptive treatment | <input type="checkbox"/> Salvage therapy | <input type="checkbox"/> Asymptomatic infection (CMV) |
| <input type="checkbox"/> Documented infection | <input type="checkbox"/> Follow-up treatment | <input type="checkbox"/> Other (specify): |

BLOOD SAMPLING AT STEADY STATE:

- | | |
|--|---|
| <input type="checkbox"/> Through level (5 min. before next dose) | <input type="checkbox"/> Peak level (Only for protocols or for clinical exceptions on request of the specialist: Antibiotic/antifungal agents: 1 hr after the end of i.v. infusion or 2 hr after an oral dose; Antiviral drugs: 3 hr post dose, except for oseltamivir: 4 hr post dose) |
|--|---|

CLINICAL DATA:

Organ dysfunction:	<input type="checkbox"/> heart	<input type="checkbox"/> liver	Immunosuppression:	<input type="checkbox"/> neutropenia
	<input type="checkbox"/> lung	<input type="checkbox"/> none		<input type="checkbox"/> long-term corticosteroids
	<input type="checkbox"/> other (specify):			<input type="checkbox"/> other (specify):
Graft:	<input type="checkbox"/> heart	<input type="checkbox"/> hematopoietic allograft	Renal function:	<input type="checkbox"/> renal insufficiency
	<input type="checkbox"/> liver	<input type="checkbox"/> hematopoietic autograft		serum creatinine: μmol/L
	<input type="checkbox"/> kidney	<input type="checkbox"/> other (specify):		<input type="checkbox"/> hemodialysis
	<input type="checkbox"/> lung			<input type="checkbox"/> continuous renal replacement therapy
				<input type="checkbox"/> other (specify):
Adverse events:	<input type="checkbox"/> none		Weight: kg	Height: cm
	<input type="checkbox"/> hepatic (specify):		For preterm babies, gestational age:	
	<input type="checkbox"/> renal (specify):		Co-medications:	
	<input type="checkbox"/> neurologic (specify):			
	<input type="checkbox"/> other (specify):			

Request for clinical interpretation of drug level measurement

yes (by default) no



Material K-EDTA whole blood (4.9 ml S-Monovette) sample received frozen
sent: citrate blood « coagulation » (S-Monovette, 2.7 ml) sample received by carrier
 fluoride/oxalate blood (BD Vacutainer, 2 or 4 ml)

ANTIMICROBIAL AGENT TO BE MEASURED

ANTIBIOTICS:

Carbapenems:

Ertapenem
 Imipenem
 Meropenem

Quinolones:

Ciprofloxacin
 Levofloxacin

Cephalosporins:

Cefepime
 Ceftazidime
 Ceftriaxone
 Ceftobiprole
 Cefuroxime

Penicillins:

Amoxicillin
 Flucloxacillin
 Piperacillin/tazobactam

Tetracyclines:

Doxycycline
 Tygecycline

Other antibiotics:

Clindamycin
 Daptomycin
 Linezolid
 Trimethoprim/sulfamethoxazole

ANTIFUNGALS:

Triazole derivates:

Fluconazole
 Itraconazole / hydroxy-itraconazole
 Posaconazole
 Voriconazole

Echinocandins:

Anidulafungin
 Caspofungin

ANTIVIRALS:

Aciclovir
 Valaciclovir
 Ganciclovir
 Valganciclovir
 Oseltamivir carboxylate

INFORMATION ON LAST DOSE ADMINISTRATION (REQUIRED)

Exact date of last dose administration:

Day: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31
 Month: 1 2 3 4 5 6 7 8 9 10 11 12

Exact time of last dose administration:

Hour: 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
 Min.: 15 30 45

Date of onset of treatment or last change in drug dose:

Dosing schedule:

Dose (mg): 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 2 3 4 5 6 7 8 9 10 20 30 40 50 60 70 80 90
100 200 300 400 500 600 700 800 900 1000 2000 3000 4000 5000 6000 7000 8000 9000
 Number of dose(s) /24h: 1 2 3 4 5 6
 (example : for a 1500 mg dose, tick the box 1000 and the box 500)

Administration route: oral i.v. i.v. continuous infusion Duration of infusion:

Other dosage:

ESSENTIAL INFORMATION FOR THE INTERPRETATION OF THE RESULTS

Bacterial infection:

clinically documented (specify):

microbiologically documented (specify):

pathogen(s):

Fungal infection:

Invasive aspergillosis
 Invasive candidiasis
 Other mycosis (specify):

Viral infection:

Cytomegalovirus disease (CMV)
 Influenza *Viral subtype identified:*

Post-exposure prophylaxis (Influenza)
 Other viral infection (specify):

Generalities:

Localization of infection (specify):

In vitro sensitivity of pathogen to the current treatment:

susceptible intermediate resistant

Minimal inhibitory concentration (MIC) of the antibiotic/antifungal agent: mg/L

Inhibitory concentration 50 (IC₅₀) of the antiviral: mg/L

Severity of infection: sepsis
 severe sepsis
 septic shock

Response of infection to the antibiotic/antifungal agent or to the antiviral drug: complete partial
 stable deterioration

- **Ship without delay** the blood sample at the centralized laboratory reception desk (maximum 30 min. after sampling).
 - *Processing of blood samples:* centrifugation at 2500 rpm during 15 minutes, freezing of plasma at -80°C within 1 hr of sampling.
 If this timing cannot be respected, keep the sample at 4°C until centrifugation and freezing (**max. 6h**).
 - **Inappropriate processing/storage/shipment can influence the reliability of the analyses/of their clinical interpretation.**